The Neat-HER virtual registry: Updated results on HER2+breast cancer patients receiving neratinib as extended adjuvant therapy.

被引：0
|
作者：
Vidal, Gregory A.
Tripathy, Debu
Hill, Nina
Lalla, Deepa
Hanson, Gillian
Drozd, Daniel R.
Xu, Feng
Rugo, Hope S.
机构：
[1] West Canc Ctr & Res Inst, Memphis, TN USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Calif San Francisco, Puma Biotechnol Inc, San Francisco, CA 94143 USA
[4] Puma Biotechnol Inc, Los Angeles, CA USA
[5] PicnicHealth, San Francisco, CA USA
[6] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e13565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13565
引用
收藏
页数：3
相关论文
共 50 条
  • [31] COSTS OF RECURRENCE IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Albanell, J.
    Colomer, R.
    Martin, M.
    Martinez, D.
    Arroyo, I
    Moreno, E.
    VALUE IN HEALTH, 2020, 23 : S435 - S435
  • [32] Long-term hazard of recurrence in HER2+breast cancer patients untreated with anti-HER2 therapy
    Strasser-Weippl, Kathrin
    Horick, Nora
    Smith, Ian E.
    O'Shaughnessy, Joyce
    Ejlertsen, Bent
    Boyle, Frances
    Buzdar, Aman U.
    Fumoleau, Pierre
    Gradishar, William
    Martin, Miguel
    Moy, Beverly
    Piccart-Gebhart, Martine
    Pritchard, Kathleen I.
    Lindquist, Deborah
    Rappold, Erica
    Finkelstein, Dianne M.
    Goss, Paul E.
    BREAST CANCER RESEARCH, 2015, 17
  • [33] Optimizing combination therapy in a murine model of HER2+breast cancer?
    Lima, Ernesto A. B. F.
    Wyde, Reid A. F.
    Sorace, Anna G.
    Yankeelov, Thomas E.
    COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING, 2022, 402
  • [34] Budesonide and loperamide do not impact the cytotoxicity of neratinib or HER2-directed monoclonal antibodies in HER2+breast cancer cell lines
    Collins, D. M.
    Gaynor, N.
    Conlon, N.
    Gullo, G.
    Eustace, A. J.
    Crown, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Engineered nanomaterials as an effective tool for HER2+breast cancer therapy
    Pandey, Prashant
    Arya, Dilip Kumar
    Ramar, Mohan Kumar
    Chidambaram, Kumarappan
    Rajinikanth, P. S.
    DRUG DISCOVERY TODAY, 2022, 27 (09) : 2526 - 2540
  • [36] Is hormone therapy alone efficacious as postoperative adjuvant therapy in Japanese Stage I, HR+/HER2+breast cancer patients?
    Ogiya, A.
    Kikutani, M.
    Nishikawa, N.
    Tadokoro, Y.
    Tanaka, K.
    Uematsu, T.
    Watanabe, J.
    Kasami, M.
    Yamasaki, S.
    Takahashi, K.
    BREAST, 2011, 20 : S68 - S68
  • [37] Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+breast cancer
    Iwata, H.
    Yamamoto, N.
    Masuda, N.
    Bando, H.
    Kuroi, K.
    Ohno, S.
    Kasai, H.
    Morita, S.
    Sakurai, T.
    Toi, M.
    BREAST, 2015, 24 : S95 - S95
  • [38] Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients
    Vici, P.
    Viola, G.
    Botti, C.
    Rossi, S.
    Vitucci, C.
    Corsetti, S.
    Di Lauro, L.
    Sergi, D.
    Foggi, P.
    Perri, P.
    Tirellil, C.
    Mottolese, M.
    Fattoruso, S. I. S.
    Lopez, M.
    CLINICA TERAPEUTICA, 2008, 159 (06): : 449 - 452
  • [39] Multicentric observational study to assess clinical characteristics of HER2-positive breast cancer patients treated with adjuvant anti-HER2 therapy.
    Segui, M.
    Llararmendi, J.
    Florian Gerico, J.
    Garcia Lopez, M.
    Esteban, B.
    Puertas Alvarez, J.
    Adrover, E.
    Ayuga, S.
    Batista, J.
    Blancas, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Factors associated with non use of adjuvant trastuzumab in older patients with HER2+breast cancer.
    Luis, Ines Vaz
    Lin, Nancy U.
    Keating, Nancy Lynn
    Barry, William Thomas
    Lii, Joyce
    Burstein, Harold J.
    Winer, Eric P.
    Freedman, Rachel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345